BUSINESS

• Gilead Japan Eyes Cancer, Inflammatory Disease Meds to Raise Profile as Specialty Pharma
  October 13, 2016

• Patient Enrollment for Tepotinib PII Begins in Japan: Merck Serono
  October 13, 2016

• 69.2% Response Rate Seen in Lenvatinib, Pembrolizumab Combination: Eisai
  October 13, 2016

• Daiichi Sankyo Kicks Off Quizartinib Global PIII for 1st-Line AML
  October 13, 2016

• Takeda to Tighten R&D Focus, Strengthen Collaboration with Outside Parties; Main Challenge Will Be Financial
  October 13, 2016

• Pfizer’s Cancer Research Selected for Feasibility Study under AMED Program; Applied Jointly with Mie Univ. and Other Partners
  October 13, 2016

• Interview: Teva Exec Says Takeda JV Can Grow Profit despite Generic Price Declines
  October 12, 2016

• Takeda, UK’s Crescendo Cut Collaboration Deal on Cancer Therapeutics
  October 12, 2016

• Daiichi Sankyo’s ADC DS-8201a Well-Tolerated in PI
  October 12, 2016

• There Will Be Consolidation in Japan Generic Space: Teva Exec
  October 11, 2016

• Teva-Takeda JV Eyes Top Spot in Off-Patent Drug Market: CEO
  October 11, 2016

• Astellas Suits Actavis Elizabeth in US over Myrbetriq Patent
  October 11, 2016

• Companion Diagnostics for Opdivo, Keytruda Pending Approval: Agilent Japan Head
  October 7, 2016

• Santen, RIKEN, FBRI Sign Drug Discovery Deal for Retinal Disease
  October 7, 2016

• Teikoku Seiyaku, Mitsubishi Tanabe Hook Up on Sales of Anti-Allergy Agents
  October 6, 2016

• GHIT Fund to Invest 1.1 Billion Yen in Development of Neglected Disease Drugs
  October 6, 2016

• Eurofarma Gets Latin American Rights to Eisai’s Cancer Candidate Farletuzumab
  October 5, 2016

• Daiichi Sankyo, AgonOx Ink Immuno-Oncology Research Collaboration
  October 5, 2016

• Marc van der Heijden to Lead Allergan Japan
  October 4, 2016

• Daiichi Sankyo Launches Large-Scale Research in Elderly NVAF Patients
  October 4, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 444
• 445
• 446
• 447
• 448
• 449
• 450
• 451
• 452
• …
• Next ›
• 最終 »